← Russell 3000 cross-section

ALEC Alector, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$275m
Revenue TTM
$14m
Net income TTM
$-118m
Free cash flow
$-158m
Composite score
Sector rank
#2720

Valuation

P / E
EV / EBITDA
EV / sales
7.4
FCF yield
-57.55%
Earnings yield vs 10-yr
-47.57pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-850.1%
EBITDA margin
ROE
1,182.1%
ROIC
Revenue growth
-82.9%

Insider activity, last 90 days

Net open-market
$-0.23m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenue to date has been primarily related to the AbbVie Agreement and GSK Agreement for the license and co-development of product candidates with those parties. We recognized revenue from the upfront payments and the milestone payment received from AbbVie over time as services were provided. We expect that our revenue will be derived primarily from the GSK Agreement in the near term. The balance of deferred revenue was $162.9 million as of June 30, 2026, related to the GSK Agreement. …Alector, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →